The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group
The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group
复制标题
DOI：
10.1093/annonc/mdm077
复制
发表时间：
2007-06-01
影响因子：
50.5
通讯作者：
Seymour, L.
中科院分区：
文献类型：
--
作者：
Laurie, S. A.;Ding, K.;Seymour, L.
背景资料：贫血和放化疗结果之间的关联已在几种恶性肿瘤中得到证实，但局限性小细胞肺癌（LD-SCLC）的数据很少。加拿大国家癌症研究所临床试验小组对两项LD-SCLC随机临床试验中的652名患者进行了联合分析，以探讨基线贫血与治疗期间出现的贫血之间的关系，以及这种癌症的放化疗结果。总生存期和局部控制与基线血红蛋白水平和治疗期间血红蛋白水平的关系（最低血红蛋白（Hb）和从基线值下降的最大百分比）进行了探讨。在三分之一的患者中发现了基线贫血，在男性、体能状态较差的患者和乳酸脱氢酶升高的患者中更常见;所有这些因素都与生存期缩短相关。在多变量分析中，血红蛋白下降幅度最大的患者局部控制改善的趋势并不显著。结论：贫血在LD-SCLC患者中很常见。诊断时的贫血可能与治疗期间出现的贫血有不同的预后意义，纠正贫血可能对结局没有影响。
Background: Associations between anemia and outcomes of chemoradiation have been documented in several malignancies, but few data exist for limited small-cell lung cancer (LD-SCLC). This combined analysis of 652 patients in two randomized clinical trials in LD-SCLC carried out by the National Cancer Institute of Canada Clinical Trials Group was undertaken to explore the relationship between anemia at baseline and anemia arising during therapy, and outcomes of chemoradiation in this cancer.Patients and methods: The relationships between overall survival and local control with hemoglobin levels at baseline and those arising during therapy (nadir hemoglobin (Hb) and maximum percentage drop from baseline values) were explored.Results: No Hb parameter was associated with either outcome. Baseline anemia was found in one-third of patients, was more common in males, in those with a poorer performance status and those with an elevated lactate dehydrogenase; all of these latter factors were associated with shorter survival. A trend towards improved local control in patients with the greatest drop in their Hb did not remain significant in a multivariate analysis.Conclusions: Anemia is common in patients with LD-SCLC. Anemia at diagnosis may have a different prognostic implication than that arising during therapy, and correction of anemia may have no impact on outcomes.